Astrotech Corp (ASTC) - Form 10-K Summary
Business Context and Reporting Period
Company: Astrotech Corporation (Nasdaq: ASTC)
Filing Type: Annual Report (Form 10-K)
Fiscal Year Ended: June 30, 2025
Business Overview: Astrotech commercializes the Astrotech Mass Spectrometer Technology (AMS Technology) platform through wholly-owned subsidiaries. Key business units include 1st Detect (security/explosives detection), AgLAB (hemp/cannabis distillation), BreathTech (breath analysis), Pro-Control (industrial process control), and EN-SCAN (environmental testing). The company is a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Revenue | $1,049 | $1,664 |
| Cost of Revenue | $574 | $913 |
| Gross Profit | $475 | $751 |
| Gross Margin | 45.3% | 45.1% |
| Operating Expenses | $15,209 | $14,031 |
| Net Loss | $(13,850) | $(11,666) |
| Net Loss Per Share (Basic/Diluted) | $(8.32) | $(7.12) |
| Cash and Cash Equivalents | $3,100 | $10,442 |
| Short-Term Investments | $15,108 | $21,474 |
| Total Assets | $26,989 | $37,640 |
| Accumulated Deficit | $(250,870) | $(237,020) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 37.0% to $1.0 million, primarily due to a reduction in TRACER 1000 unit sales compared to the prior year.
- Increased Operating Expenses: Total operating expenses rose 8.4% to $15.2 million. Research and Development (R&D) expenses increased 19.9% ($1.4 million) due to spending on contractors and employees for mass spectrometry and gas chromatography development. Selling, General, and Administrative (SG&A) expenses decreased slightly by 2.4%.
- Liquidity Position: Cash and cash equivalents dropped significantly from $10.4 million to $3.1 million, a decrease of $7.3 million, driven by funding continuing operating expenses. Short-term investments also declined from $21.5 million to $15.1 million.
- Lease Obligations: Operating lease right-of-use assets and liabilities increased significantly (by approximately $2.1 million and $2.2 million, respectively) due to entering a new lease for the "Metric facility" in Austin, Texas, commencing July 1, 2025.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Product Milestones: The company secured its first TSA-approved sale of the TRACER 1000 ETD ($429,000 order) and launched the TRACER 1000 Narcotic Trace Detector (NTD). A DHS R&D contract was awarded for next-generation explosives detection.
- Expansion: New subsidiaries Pro-Control and EN-SCAN were formed to target industrial process control and environmental testing markets, respectively.
- Capital Needs: Management states that current cash and investments are sufficient to fund operations for at least twelve months. However, the company anticipates continued losses and will likely need to raise additional capital through equity or debt financing to fund R&D and commercialization, which may result in shareholder dilution.
Key Risks & Contingencies:
- Regulatory Approval: Commercialization of the BreathTest-1000 requires FDA clearance, which is uncertain and costly. TSA checkpoint certification for the TRACER 1000 is ongoing.
- Customer Concentration: Revenue is highly concentrated; four customers comprised substantially all revenue in 2025, and three in 2024. None have long-term contracts.
- Cannabis Industry Risk: The AgLAB business is tied to the hemp/cannabis market, which faces federal illegality (Schedule I) and evolving state regulations, creating potential legal and operational risks.
- Intellectual Property: The company faces risks of third-party infringement claims and has recently addressed unauthorized resellers of the TRACER 1000.
- Supply Chain: Manufacturing relies on third-party suppliers, including single-source suppliers for critical components, creating vulnerability to shortages.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.2 million in liquid assets (cash + short-term investments) against the $13.8 million annual burn rate and the new $3.0 million lease obligation.
- TSA Certification Status: Confirm the timeline and probability of the TRACER 1000 moving from Stage II testing to the "qualified" list for checkpoint screening.
- Customer Diversification: Assess the risk associated with the top four customers representing nearly 100% of revenue without long-term contracts.
- FDA Pathway: Review the specific regulatory strategy and estimated costs for the BreathTest-1000 510(k) or de novo clearance.
- Lease Commitments: Evaluate the impact of the new Metric facility lease ($3.0 million total obligation) on future cash flows.